{
    "info": {
        "nct_id": "NCT03715933",
        "official_title": "An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas",
        "inclusion_criteria": "1. Males or females aged ≥12 to less than 85 years for Ewing sarcoma and 18 to less than 85 years of age for other tumors.\n2. Part 3 combination therapy expansion tumor types:\n\n   * Histologically confirmed Ewing sarcoma with a classical fusion: Patients with locally advanced or metastatic, unresectable, relapsed, or refractory disease who have received at least 1 but no more than 2 prior lines of systemic treatment with a preferred first line chemotherapy regimens.\n   * Colorectal adenocarcinoma: Patients with locally advanced or metastatic, unresectable disease, who have received at least 2 but no more than 3 prior lines of systemic therapy.\n3. Measurable disease as defined by RECISTv1.1 (or modified RECIST for mesothelioma) criteria.\n4. Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.\n5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1, or Karnofsky Performance Status score of ≥60, or Lansky Play-Performance Scale for Children score ≥60 (for patients less than 16 years).\n6. Estimated life expectancy of at least 12 weeks.\n7. Availability of archival tissue or fresh cancer biopsy are mandatory.\nHealthy volunteers allowed\nMust have minimum age of 12 Years\nMust have maximum age of 85 Years",
        "exclusion_criteria": "1. Prior treatment with or exposure to DR5 agonists.\n2. Receipt of any anticancer therapy (including investigational agents) within 4 weeks or within 5 half-lives prior to the first dose of study treatment. Exceptions per protocol.\n3. Allergy or sensitivity to INBRX-109 or known allergies to CHO-produced antibodies.\n4. Receipt of radiotherapy within 4 weeks prior to the first dose of study treatment, and liver-directed within 12 months prior to the first dose of study drug.\n5. Subject has undergone allogeneic hematopoietic stem cell or bone marrow transplantation within the last 5 years. Exceptions per protocol.\n6. Prior or concurrent malignancies. Exceptions per protocol.\n7. Hematologic malignancies.\n8. Symptomatic active primary CNS tumors, leptomeningeal disease, and CNS metastases. Exceptions per protocol. Patients with any evidence or history of multiple sclerosis (MS) or other demyelinating disorders are excluded.\n9. Chronic liver diseases including fatty liver. Exception: Patients < 45 years old with fatty liver disease may be accepted as long as adequate hepatic function as defined in the inclusion/exclusion criteria is confirmed.\n10. Acute viral or toxic liver disease within 12 months prior to the first dose of study drug.\n11. Evidence or history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.\n12. Known sensitivity or contraindications to the following drugs:\n\n    * Ewing sarcoma: irinotecan or TMZ\n    * colorectal adenocarcinoma: FU, leucovorin, or irinotecan\n13. Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart disease less than 3 months prior to enrollment.\n14. Acute, hemodynamically significant deep vein thrombosis or clinically significant pulmonary embolism not resolved or stable for at least 3 months prior to the start of study treatment.\n15. Major surgery within 4 weeks prior to enrollment on this trial.\n16. Systemic infection requiring antibiotics within 2 weeks prior to the first dose of study drug.\n17. Other exclusion criteria per protocol.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "3. Measurable disease as defined by RECISTv1.1 (or modified RECIST for mesothelioma) criteria.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease as defined by RECISTv1.1 (or modified RECIST for mesothelioma) criteria",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "RECISTv1.1 (or modified RECIST for mesothelioma) criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Part 3 combination therapy expansion tumor types:",
            "criterions": [
                {
                    "exact_snippets": "Part 3 combination therapy expansion tumor types",
                    "criterion": "tumor type",
                    "requirements": [
                        {
                            "requirement_type": "inclusion in Part 3 combination therapy expansion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 85 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 85 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 85,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 12 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 12 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Availability of archival tissue or fresh cancer biopsy are mandatory.",
            "criterions": [
                {
                    "exact_snippets": "Availability of archival tissue ... are mandatory",
                    "criterion": "archival tissue",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Availability of ... fresh cancer biopsy are mandatory",
                    "criterion": "fresh cancer biopsy",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic ... function as defined per protocol",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... coagulation ... function as defined per protocol",
                    "criterion": "coagulation function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic ... function as defined per protocol",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal function as defined per protocol",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Estimated life expectancy of at least 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Estimated life expectancy of at least 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Colorectal adenocarcinoma: Patients with locally advanced or metastatic, unresectable disease, who have received at least 2 but no more than 3 prior lines of systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Colorectal adenocarcinoma",
                    "criterion": "colorectal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic, unresectable disease",
                    "criterion": "disease stage and resectability",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "resectability",
                            "expected_value": "unresectable"
                        }
                    ]
                },
                {
                    "exact_snippets": "have received at least 2 but no more than 3 prior lines of systemic therapy",
                    "criterion": "prior lines of systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Males or females aged ≥12 to less than 85 years for Ewing sarcoma and 18 to less than 85 years of age for other tumors.",
            "criterions": [
                {
                    "exact_snippets": "Males or females",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "aged ≥12 to less than 85 years for Ewing sarcoma",
                    "criterion": "age (Ewing sarcoma)",
                    "requirements": [
                        {
                            "requirement_type": "age_range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 85,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "18 to less than 85 years of age for other tumors",
                    "criterion": "age (other tumors)",
                    "requirements": [
                        {
                            "requirement_type": "age_range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 85,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed Ewing sarcoma with a classical fusion: Patients with locally advanced or metastatic, unresectable, relapsed, or refractory disease who have received at least 1 but no more than 2 prior lines of systemic treatment with a preferred first line chemotherapy regimens.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed Ewing sarcoma with a classical fusion",
                    "criterion": "Ewing sarcoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "fusion type",
                            "expected_value": "classical"
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic, unresectable, relapsed, or refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "locally advanced",
                                "metastatic",
                                "unresectable",
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have received at least 1 but no more than 2 prior lines of systemic treatment",
                    "criterion": "prior lines of systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with a preferred first line chemotherapy regimens",
                    "criterion": "first line chemotherapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "regimen type",
                            "expected_value": "preferred first line chemotherapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1, or Karnofsky Performance Status score of ≥60, or Lansky Play-Performance Scale for Children score ≥60 (for patients less than 16 years).",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1",
                    "criterion": "ECOG Performance Status score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Karnofsky Performance Status score of ≥60",
                    "criterion": "Karnofsky Performance Status score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Lansky Play-Performance Scale for Children score ≥60 (for patients less than 16 years)",
                    "criterion": "Lansky Play-Performance Scale for Children score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "6. Prior or concurrent malignancies. Exceptions per protocol.",
            "criterions": [
                {
                    "exact_snippets": "Prior or concurrent malignancies",
                    "criterion": "malignancies",
                    "requirements": [
                        {
                            "requirement_type": "temporal occurrence",
                            "expected_value": [
                                "prior",
                                "concurrent"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Acute, hemodynamically significant deep vein thrombosis or clinically significant pulmonary embolism not resolved or stable for at least 3 months prior to the start of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Acute, hemodynamically significant deep vein thrombosis ... not resolved or stable for at least 3 months prior to the start of study treatment",
                    "criterion": "deep vein thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "acuteness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hemodynamic significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "resolution or stability duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant pulmonary embolism not resolved or stable for at least 3 months prior to the start of study treatment",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "resolution or stability duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Acute viral or toxic liver disease within 12 months prior to the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Acute viral or toxic liver disease within 12 months prior to the first dose of study drug.",
                    "criterion": "acute viral liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Acute viral or toxic liver disease within 12 months prior to the first dose of study drug.",
                    "criterion": "acute toxic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Other exclusion criteria per protocol.",
            "criterions": [
                {
                    "exact_snippets": "Other exclusion criteria per protocol.",
                    "criterion": "other exclusion criteria per protocol",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior treatment with or exposure to DR5 agonists.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with or exposure to DR5 agonists",
                    "criterion": "DR5 agonists",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment or exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Allergy or sensitivity to INBRX-109 or known allergies to CHO-produced antibodies.",
            "criterions": [
                {
                    "exact_snippets": "Allergy or sensitivity to INBRX-109",
                    "criterion": "allergy or sensitivity to INBRX-109",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known allergies to CHO-produced antibodies",
                    "criterion": "allergy to CHO-produced antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* colorectal adenocarcinoma: FU, leucovorin, or irinotecan",
            "criterions": [
                {
                    "exact_snippets": "colorectal adenocarcinoma",
                    "criterion": "colorectal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "FU, leucovorin, or irinotecan",
                    "criterion": "prior treatment with FU, leucovorin, or irinotecan",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": [
                                "FU",
                                "leucovorin",
                                "irinotecan"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ewing sarcoma: irinotecan or TMZ",
            "criterions": [
                {
                    "exact_snippets": "Ewing sarcoma",
                    "criterion": "Ewing sarcoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "irinotecan or TMZ",
                    "criterion": "prior treatment with irinotecan or TMZ",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": [
                                "irinotecan",
                                "TMZ"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Chronic liver diseases including fatty liver. Exception: Patients < 45 years old with fatty liver disease may be accepted as long as adequate hepatic function as defined in the inclusion/exclusion criteria is confirmed.",
            "criterions": [
                {
                    "exact_snippets": "Chronic liver diseases including fatty liver",
                    "criterion": "chronic liver diseases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "fatty liver",
                    "criterion": "fatty liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients < 45 years old with fatty liver disease may be accepted as long as adequate hepatic function ... is confirmed",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 45,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate hepatic function as defined in the inclusion/exclusion criteria is confirmed",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart disease less than 3 months prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart disease less than 3 months prior to enrollment.",
                    "criterion": "clinically significant cardiac condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "examples",
                            "expected_value": [
                                "myocardial infarction",
                                "uncontrolled angina",
                                "cerebrovascular accident",
                                "other acute uncontrolled heart disease"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Known sensitivity or contraindications to the following drugs:",
            "criterions": [
                {
                    "exact_snippets": "Known sensitivity or contraindications to the following drugs",
                    "criterion": "sensitivity or contraindications to specified drugs",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Receipt of radiotherapy within 4 weeks prior to the first dose of study treatment, and liver-directed within 12 months prior to the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Receipt of radiotherapy within 4 weeks prior to the first dose of study treatment",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "receipt_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first dose of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "liver-directed within 12 months prior to the first dose of study drug",
                    "criterion": "liver-directed radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "receipt_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months prior to first dose of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Hematologic malignancies.",
            "criterions": [
                {
                    "exact_snippets": "Hematologic malignancies.",
                    "criterion": "hematologic malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Subject has undergone allogeneic hematopoietic stem cell or bone marrow transplantation within the last 5 years. Exceptions per protocol.",
            "criterions": [
                {
                    "exact_snippets": "Subject has undergone allogeneic hematopoietic stem cell or bone marrow transplantation within the last 5 years",
                    "criterion": "allogeneic hematopoietic stem cell or bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Receipt of any anticancer therapy (including investigational agents) within 4 weeks or within 5 half-lives prior to the first dose of study treatment. Exceptions per protocol.",
            "criterions": [
                {
                    "exact_snippets": "Receipt of any anticancer therapy (including investigational agents) within 4 weeks or within 5 half-lives prior to the first dose of study treatment",
                    "criterion": "anticancer therapy (including investigational agents)",
                    "requirements": [
                        {
                            "requirement_type": "receipt within time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Systemic infection requiring antibiotics within 2 weeks prior to the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Systemic infection requiring antibiotics within 2 weeks prior to the first dose of study drug.",
                    "criterion": "systemic infection requiring antibiotics",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to first dose of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Symptomatic active primary CNS tumors, leptomeningeal disease, and CNS metastases. Exceptions per protocol. Patients with any evidence or history of multiple sclerosis (MS) or other demyelinating disorders are excluded.",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic active primary CNS tumors",
                    "criterion": "primary CNS tumors",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic and active presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any evidence or history of multiple sclerosis (MS)",
                    "criterion": "multiple sclerosis (MS)",
                    "requirements": [
                        {
                            "requirement_type": "evidence or history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "other demyelinating disorders",
                    "criterion": "other demyelinating disorders",
                    "requirements": [
                        {
                            "requirement_type": "evidence or history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Major surgery within 4 weeks prior to enrollment on this trial.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks prior to enrollment on this trial.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "11. Evidence or history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.",
            "criterions": [
                {
                    "exact_snippets": "Evidence or history of hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "evidence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Evidence or history of hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "evidence or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Evidence or history of ... human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "evidence or history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}